VEC Vectura Group Plc

TIDMVEC

RNS Number : 7233C

Vectura Group plc

19 April 2017

Vectura Group plc

External audit tender process successfully concluded

Chippenham, UK - 19 April 2017: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading device and formulation business for inhaled airways products, announces the successful conclusion of a tender process for the provision of its external audit starting from the 2017 financial year.

As a result, a proposal will be made to shareholders at the 2017 Annual General Meeting being held on 25 May 2017 to appoint KPMG LLP as external auditor.

This proposal is the result of a competitive process undertaken by the Audit Committee, as anticipated in its report in the Company's Annual Report and Accounts for the year ended 31 March 2016, concluding with a recommendation approved by the Board. Deloitte had been the external auditor since 2007. Further details of the tender process are included in the Company's Report and Accounts for the period ended 31 December 2016 which will be sent to shareholders on 24 April 2017.

- Ends -

Enquiries

 
Vectura Group plc                                               +44 (0)1249 667700 
 
Andrew Derodra - Chief Financial Officer 
 Fleur Wood - Director Communications 
 Elizabeth Knowles - Director Investor Relations and Analysis 
John Murphy - Company Secretary 
Consilium Strategic Communications                              +44 (0)20 3709 5700 
Mary-Jane Elliot / Sue Stuart / Jessica Hodgson 
 

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBGGDSDDBBGRC

(END) Dow Jones Newswires

April 19, 2017 06:24 ET (10:24 GMT)

Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024

Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024